Annual Report & Accounts for the year ended 30 April 2016
Sustained growth through innovation and diversification
Consort Medical has delivered another year of continued and consistent organic growth in the Bespak business, whilst expanding its future growth opportunities from both its development portfolio and its innovation pipeline.
Dr Peter Fellner
Consort has again delivered strong organic growth. In Bespak, this has once again been delivered through strong revenue growth and operating leverage.
Consort has again delivered strong financial performance in FY2016, as material organic revenue growth produced significant operating leverage and EBIT growth, with margin expansion in both businesses.
A leading global CDMO providing advanced delivery technologies, formulation and manufacturing solutions for drugs.